Steve Bates OBE, Chief Executive of the Bioindustry Association said: “This is not a panacea. Just handing countries governments a recipe book without the ingredients, safeguards, infrastructure, and sizable workforce with the high skills needed to deliver safe and effective vaccines, will not speedily deliver help to all those that need it.
UK biotech companies are on track for a record-breaking year of fundraising according to the latest data released by the UK BioIndustry Association (BIA) and Clarivate. More than £830m in fresh capital was raised in the three months to the end of February, almost topping the £894m raised in the first six months of 2020, which itself was a record-breaking year.
Steve Bates OBE, Chief Executive of the BioIndustry Association said: “Congratulations to the Government’s new Office for Investment for securing the £1 billion UAE-UK Sovereign Investment Partnership, which I am delighted to see focused on the opportunities in UK life sciences.
Reacting to the news of Touchlight's £42m investment round, Steve Bates OBE, Chief Executive of the BioIndustry Association said: “UK biotech and life sciences companies have been at the heart of understanding, supporting and leading the manufacture and scale up of COVID-19 vaccines. The investment into Touchlight will give the UK further manufacturing capability in mRNA vaccines and in the innovative field of cell and gene therapies, which will benefit UK patients enormously in the years to come.”
Reacting to new that eXmoor pharma has secured £12m of investment, Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) said: “This is great news for UK medicine manufacturing. The investment into eXmoor’s cutting edge process development and clinical manufacturing in the south west of England will create long term highly skilled jobs. Anchoring next generation scale up and manufacturing in the UK will help ensure NHS patients will be amongst the first to benefit from new gene therapies as they develop in the coming years.”
Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA), said:
"The COVID-19 pandemic has shown the strategic necessity for the UK to have a thriving domestic life sciences and biotech sector. Companies and researchers from across the UK have led in the global effort to develop, manufacture and deploy the COVID-19 vaccines, therapies and diagnostics needed to re-open the global economy. As the Prime Minister made clear last week, this successful public-private partnership is the formula for our country’s prosperity for years to come, a strong and active government investing massively in science and technology, coupled with a dynamic enterprise economy.
Dr David Atkins, Chief Executive Officer of Congenica, has joined the National Genomics Board as the BioIndustry Association (BIA)’s SME representative. The Board brings together senior decision makers from government, the NHS, academia and industry to advise the UK Government on its national genomics strategy, Genome UK. Dr Atkins’ appointment to the Board means that the voice of genomic start-ups and SMEs will be heard at the highest levels of government.